0IK Stock Overview
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NGM Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$4.06 |
| 52 Week Low | US$0.55 |
| Beta | 1.27 |
| 1 Month Change | 2.17% |
| 3 Month Change | 34.29% |
| 1 Year Change | -60.17% |
| 3 Year Change | -93.53% |
| 5 Year Change | -89.68% |
| Change since IPO | -88.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.4% | 1.5% | -0.5% |
| 1Y | -60.2% | -27.9% | 2.5% |
Return vs Industry: 0IK underperformed the German Pharmaceuticals industry which returned -29.5% over the past year.
Return vs Market: 0IK underperformed the German Market which returned 5.5% over the past year.
Price Volatility
| 0IK volatility | |
|---|---|
| 0IK Average Weekly Movement | 11.8% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0IK's share price has been volatile over the past 3 months.
Volatility Over Time: 0IK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 138 | David Woodhouse | www.ngmbio.com |
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy.
NGM Biopharmaceuticals, Inc. Fundamentals Summary
| 0IK fundamental statistics | |
|---|---|
| Market cap | €118.64m |
| Earnings (TTM) | -€131.41m |
| Revenue (TTM) | €4.08m |
29.1x
P/S Ratio-0.9x
P/E RatioIs 0IK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IK income statement (TTM) | |
|---|---|
| Revenue | US$4.42m |
| Cost of Revenue | US$114.23m |
| Gross Profit | -US$109.81m |
| Other Expenses | US$32.56m |
| Earnings | -US$142.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | -2,486.12% |
| Net Profit Margin | -3,223.34% |
| Debt/Equity Ratio | 0% |
How did 0IK perform over the long term?
See historical performance and comparison